@article{470c2c9698464851851a987f1564c871,
title = "Dual Antiplatelet Therapy in the Management of Acute Minor Ischemic Stroke and High-Risk Transient Ischemic Attack: An Expert Consensus Statement From Taiwan Stroke Society and Taiwan Society of Emergency Medicine",
abstract = "The aim of this review is to achieve a consensus between Taiwan Stroke Society (TSS) and Taiwan Society of Emergency Medicine (TSEM) to manage acute non-cardioembolic minor ischemic stroke (MIS) and high-risk transient ischemic attack (TIA). The methodology is to review the recent findings from clinical trials of dual antiplatelet therapy (DAPT) from 2010 to 2021 and updates in clinical practice guidelines from 2018 to 2022 for non-cardioembolic MIS/TIA management at the acute stage. Four leading clinical studies, CHANCE, POINT, THALES, and CHANCE-2 along with other relevant studies introducing DAPT, are discussed in this review. The risk-benefit profile between stroke recurrence reduction and major bleeding increase is also elucidated. TSS and TSEM concluded that for patients presenting with non-cardioembolic MIS or high-risk TIA who did not receive intravenous alteplase, initiation of DAPT within 24 hours after stroke onset and continued up to 21 days, followed by antiplatelet monotherapy, is effective in reducing recurrent ischemic stroke for a period of up to 90 days.",
keywords = "acute minor ischemic stroke, consensus statement, dual antiplatelet therapy, transient ischemic attack",
author = "Chen, {Po Lin} and Chen, {Ying Ju} and Chung, {Chih Ping} and Seak, {Chen June} and Jeng, {Jiann Shing} and Hsieh, {Ming Ju} and Lien, {Li Ming} and Chen, {Jiann Hwa} and Chen, {Yu Wei} and Chiu, {Te Fa} and Lee, {Jiunn Tay} and Ng, {Chip Jin}",
note = "Funding Information: The expert panel thanks Sanofi Taiwan Co. Ltd for supporting the organization of the meeting. The meeting during which this scientific statement was formulated was funded by an unrestricted educational grant from Sanofi Taiwan Co. Ltd. The funder had no role in determining the content of the scientific statement. The writing/editorial assistance of the manuscript was supported by EMD Asia Scientific Communication (Taiwan branch) Co., Ltd. Publisher Copyright: {\textcopyright} 2022 Ainosco Press. All rights reserved.",
year = "2022",
month = sep,
day = "1",
doi = "10.6705/j.jacme.202209_12(3).0001",
language = "English",
volume = "12",
pages = "85--95",
journal = "Journal of Acute Medicine",
issn = "2211-5587",
publisher = "Elsevier B.V.",
number = "3",
}